A PYMNTS Company

US: Latest pharma merger earns antitrust clearance

By  |  January 16, 2014

Valeant Pharmaceuticals International announced Wednesday its proposed buyout of Solta medical has earned regulatory clearance due to the expiration of the HSR waiting period, according to a press release.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The merger was first announced last month as Valeant revealed a purchase price of $250 million. The transaction included a share price of $2.92, the release said.

    Full Content: RTT News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.